Pear worth $1.6 billion after listing on Nasdaq

23 June 2021

As in other industries, the rise of the special purpose acquisition company (SPAC) as a means to going public is becoming more evident in pharma and biotech.

Following SPAC mergers from Valo Health and from Roivant, the latest company to use this route to listing is Pear Therapeutics, a digital therapeutics company, which will achieve about $400 million in gross proceeds should the deal close, due in the latter part of the year.

While still relatively uncommon, SPAC mergers have become more popular, offering companies a quick and cost-effective listing with a high level of control over the process.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK